Cerberus-backed Talecris to Sell in $3.4B Deal

Talecris Biotherapeutics (NASDAQ: TLCR) has agreed to be acquired by Grifols (MC: GRF) in a deal valued at about $3.4 billion. Talecris shareholders will receive $19 in cash and 0.641 newly-issued Grifols shares for each share of common stock they own. Cerberus Capital Management currently holds an approximately 49% stake in Talecris and has agreed to vote favorably. Deutsche Bank, Nomura, BBVA, BNP Paribas, HSBC and Morgan Stanley are leading the group providing debt financing for the deal, which is expected to close in the latter half of the year.